Cochrane · systematic review · CD013154
Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age‐related macular degeneration
Yeong, JL, Loveman, E, Colquitt, JL, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
7
No studies
7
Included studies
NR
No studies 7 · 50%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 42.9%Moderate 1 · 7.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Emixustat compared to placebo for people with geographic atrophy due to AMD
Population: people with geographic atrophy due to AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA from baseline to 24 months* Emixustat vs placebo | no estimate extracted | 1 study · 320 participants | Low Downgraded: imprecision |
Proportion of participants losing ≥ 15 EDTRS letters at 24 months** Emixustat vs placebo | RR 0.91 [0.59, 1.4] | 1 study · 498 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants losing ≥ 10 EDTRS letters** Emixustat vs placebo | no estimate extracted | NR | No studies |
Progression of geographic atrophy Emixustat vs placebo | no estimate extracted | 1 study · 503 participants | Low Downgraded: risk of bias, imprecision |
Progression to advanced AMD (geographic atrophy or neovascular) Emixustat vs placebo | no estimate extracted | NR | No studies |
Mean change in macular sensitivity Emixustat vs placebo | no estimate extracted | NR | No studies |
Adverse events Emixustat vs placebo | no estimate extracted | 2 studies · 575 participants | Moderate Downgraded: risk of bias, imprecision |
Fenretinide compared to placebo for people with geographic atrophy due to AMD
Population: people with geographic atrophy due to AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA from baseline to 24 months Fenretinide vs placebo | no estimate extracted | 1 study · 246 participants | Low Downgraded: risk of bias |
Proportion of participants losing ≥ 15 EDTRS letters Fenretinide vs placebo | no estimate extracted | NR | No studies |
Proportion of participants losing ≥ 10 EDTRS letters Fenretinide vs placebo | no estimate extracted | NR | No studies |
Progression of geographic atrophy Fenretinide vs placebo | no estimate extracted | 1 study · 142 participants | Low Downgraded: risk of bias |
Progression to advanced AMD (geographic atrophy or neovascular) Fenretinide vs placebo | no estimate extracted | NR | No studies |
Mean change in macular sensitivity Fenretinide vs placebo | no estimate extracted | NR | No studies |
Adverse events Fenretinide vs placebo | no estimate extracted | 1 study · 246 participants | Low Downgraded: risk of bias |